ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
äŒæ¥ã³ãŒãIPA
äŒç€ŸåImmunoprecise Antibodies Ltd
äžå Žæ¥Jan 30, 1987
æé«çµå¶è²¬ä»»è
ãCEOãDr. Jennifer Lynne Bath, Ph.D.
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 30
æ¬ç€Ÿæåšå°Industrious 823 Congress Ave Suite 300
éœåžAUSTIN
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·78701
é»è©±çªå·16048060626
ãŠã§ããµã€ãhttps://www.ipatherapeutics.com/
äŒæ¥ã³ãŒãIPA
äžå Žæ¥Jan 30, 1987
æé«çµå¶è²¬ä»»è
ãCEOãDr. Jennifer Lynne Bath, Ph.D.
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã